Xconomy | Boston - Business + Technology in the Exponential Economy

Targanta Aims to “Simplifi” Treatment of Deadly Bugs With Single-Shot Antibiotic
Enanta Pharmaceuticals Starts Clinical Trial of Antibiotic for Drug Resistant Bacteria
Targanta Antibiotic Shown Effective in Less-Frequent Dose
Rib-X Pharma, and Its Lead Antibiotic, Gear Up for Prime Time
TetraPhase Aims to Fill the Antibiotic Pipeline—and its Executive Office

Cubist Agrees to Promote AstraZeneca Antibiotic

Cubist Pharmaceuticals, the Lexington, MA-based maker of the Cubicin antibiotic, said today it has agreed to promote Merrem, another intravenous antibiotic drug made by AstraZeneca. Cubist, (NASDAQ: CBST) will receive a minimum of $20 million a year in revenue under the deal, and the figure could go higher based on Merrem sales, the company said. “Cubist is better leveraging its commercialization resources and reinvesting the proceeds into its future,” said Thomas Russo, an analyst with Robert W. Baird, in a note to clients today.

Comments | Permalink |